These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 20829421

  • 1. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease.
    Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M.
    Clin J Am Soc Nephrol; 2011 Jan; 6(1):7-13. PubMed ID: 20829421
    [Abstract] [Full Text] [Related]

  • 2. Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.
    Heffernan KS, Kuvin JT, Sarnak MJ, Perrone RD, Miskulin DC, Rudym D, Chandra P, Karas RH, Menon V.
    Nephrol Dial Transplant; 2011 Aug; 26(8):2515-21. PubMed ID: 21292815
    [Abstract] [Full Text] [Related]

  • 3. Endothelial dysfunction and oxidative stress in polycystic kidney disease.
    Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW.
    Am J Physiol Renal Physiol; 2014 Dec 01; 307(11):F1198-206. PubMed ID: 25234311
    [Abstract] [Full Text] [Related]

  • 4. Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL, Wang W, Farmer-Bailey H, Gitomer B, Malaczewski M, Klawitter J, Jovanovich A, Chonchol M.
    Clin J Am Soc Nephrol; 2018 Oct 08; 13(10):1493-1501. PubMed ID: 30228110
    [Abstract] [Full Text] [Related]

  • 5. Kidney Energetics and Cyst Burden in Autosomal Dominant Polycystic Kidney Disease: A Pilot Study.
    Bjornstad P, Richard G, Choi YJ, Nowak KL, Steele C, Chonchol MB, Nadeau KJ, Vigers T, Pyle L, Tommerdahl K, van Raalte DH, Hilkin A, Driscoll L, Birznieks C, Hopp K, Wang W, Edelstein C, Nelson RG, Gregory AV, Kline TL, Blondin D, Gitomer B.
    Am J Kidney Dis; 2024 Sep 08; 84(3):286-297.e1. PubMed ID: 38621633
    [Abstract] [Full Text] [Related]

  • 6. Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.
    Lai S, Petramala L, Mastroluca D, Petraglia E, Di Gaeta A, Indino E, Panebianco V, Ciccariello M, Shahabadi HH, Galani A, Letizia C, D'Angelo AR.
    Medicine (Baltimore); 2016 Jul 08; 95(29):e4175. PubMed ID: 27442639
    [Abstract] [Full Text] [Related]

  • 7. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
    Wang K, Zelnick LR, Chen Y, Hoofnagle AN, Watnick T, Seliger S, Kestenbaum B.
    Clin J Am Soc Nephrol; 2020 Jan 07; 15(1):80-88. PubMed ID: 31628117
    [Abstract] [Full Text] [Related]

  • 8. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM, Meijer E, Boertien WE, Sinkeler SJ, Tent H, de Jong PE, Navis G, Gansevoort RT.
    Am J Kidney Dis; 2013 Sep 07; 62(3):531-40. PubMed ID: 23714171
    [Abstract] [Full Text] [Related]

  • 9. Early Markers of Cardiovascular Risk in Autosomal Dominant Polycystic Kidney Disease.
    Lai S, Mastroluca D, Matino S, Panebianco V, Vitarelli A, Capotosto L, Turinese I, Marinelli P, Rossetti M, Galani A, Baiocchi P, D'Angelo AR, Palange P.
    Kidney Blood Press Res; 2017 Sep 07; 42(6):1290-1302. PubMed ID: 29262409
    [Abstract] [Full Text] [Related]

  • 10. Association of OSR-1 With Vascular Dysfunction and Hypertension in Polycystic Kidney Disease.
    Kocyigit I, Taheri S, Eroglu E, Zararsiz G, Sener EF, Uzun I, Imamoglu H, Mehmetbeyoglu E, Unal A, Korkmaz K, Sipahioglu MH, Oymak O, Tokgoz B.
    Ther Apher Dial; 2020 Feb 07; 24(1):64-71. PubMed ID: 31020807
    [Abstract] [Full Text] [Related]

  • 11. Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension.
    Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Yamada S, Ueda Y, Koide H.
    Am J Med Sci; 2012 Jan 07; 343(1):46-51. PubMed ID: 21760473
    [Abstract] [Full Text] [Related]

  • 12. Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease.
    Raptis V, Georgianos PI, Sarafidis PA, Sioulis A, Makedou K, Makedou A, Grekas DM, Kapoulas S.
    Kidney Blood Press Res; 2013 Jan 07; 38(1):72-82. PubMed ID: 24577239
    [Abstract] [Full Text] [Related]

  • 13. Mean platelet volume and its relation with arterial stiffness in patients with normotensive polycystic kidney disease.
    Orscelik O, Kocyigit I, Akpek M, Dogdu O, Kaya C, Unal A, Sipahioglu M, Tokgoz B, Zengin H, Oymak O, Kaya MG.
    J Investig Med; 2013 Mar 07; 61(3):597-603. PubMed ID: 23360844
    [Abstract] [Full Text] [Related]

  • 14. Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?
    Jankowska M, Qureshi AR, Barany P, Heimburger O, Stenvinkel P, Lindholm B.
    Nephrology (Carlton); 2018 Jan 07; 23(1):31-36. PubMed ID: 27653449
    [Abstract] [Full Text] [Related]

  • 15. Systemic Succinate, Hypoxia-Inducible Factor-1 Alpha, and IL-1β Gene Expression in Autosomal Dominant Polycystic Kidney Disease with and without Hypertension.
    Kocyigit I, Taheri S, Eroglu E, Sener EF, Zararsız G, Uzun I, Tufan E, Mehmetbeyoglu E, Korkmaz Bayramov K, Sipahioglu MH, Ozkul Y, Tokgoz B, Oymak O, Axelsson J.
    Cardiorenal Med; 2019 Jan 07; 9(6):370-381. PubMed ID: 31319406
    [Abstract] [Full Text] [Related]

  • 16. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients.
    Cottone S, Mulè G, Guarneri M, Palermo A, Lorito MC, Riccobene R, Arsena R, Vaccaro F, Vadalà A, Nardi E, Cusimano P, Cerasola G.
    Nephrol Dial Transplant; 2009 Feb 07; 24(2):497-503. PubMed ID: 18772174
    [Abstract] [Full Text] [Related]

  • 17. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, Peters DJM, Gansevoort RT, on behalf of the DIPAK-1 study investigators.
    Am J Nephrol; 2019 Feb 07; 50(5):375-385. PubMed ID: 31600749
    [Abstract] [Full Text] [Related]

  • 18. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A, Lu Y, Kawano H, Horie S, Muto S.
    Clin Exp Nephrol; 2015 Dec 07; 19(6):1199-205. PubMed ID: 25715868
    [Abstract] [Full Text] [Related]

  • 19. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.
    Am J Kidney Dis; 2015 Jun 07; 65(6):833-41. PubMed ID: 25600953
    [Abstract] [Full Text] [Related]

  • 20. α-lipoic acid in patients with autosomal dominant polycystic kidney disease.
    Lai S, Petramala L, Muscaritoli M, Cianci R, Mazzaferro S, Mitterhofer AP, Pasquali M, D'Ambrosio V, Carta M, Ansuini M, Ramaccini C, Galani A, Amabile MI, Molfino A, Letizia C.
    Nutrition; 2020 Mar 07; 71():110594. PubMed ID: 31790890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.